Korean J Fam Pract 2020; 10(3): 158-163  https://doi.org/10.21215/kjfp.2020.10.3.158
Menopause
Hee Jeong Choi*, Han Jin Oh
Department of Family Medicine, Eulji University Hospital, Daejeon, Korea
Hee Jeong Choi
Tel: +82-42-611-3231, Fax: +82-42-611-3776
E-mail: ohinia@daum.net
ORCID: http://orcid.org/0000-0001-6085-5770
Received: April 13, 2020; Revised: April 16, 2020; Accepted: May 7, 2020; Published online: June 20, 2020.
© The Korean Academy of Family Medicine. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Menopause can lead to poor quality of life and health problems and is associated with an increased risk of cardiovascular disease and osteoporosis. The health goals of postmenopausal women are to maintain optimal physical, psychological, and social well-being by treating short-term and long-term health problems related to menopause and correcting risk factors for chronic diseases related to aging. The menopausal transition is an excellent opportunity for a general health assessment including assessment of chronic diseases and cancer screening. Recommendations from scientific societies clarify that initiation of menopausal hormone therapy (MHT) is appropriate for symptomatic women without contraindications when they are in the early postmenopausal period (i.e., age <60 years or within 10 years of menopause onset). The decreasing rate of MHT use and/or its premature discontinuation may lead to an increased prevalence of chronic conditions, such as cardiovascular disease and osteoporosis. Primary care physicians should be able to provide symptomatic women with the right information about the benefits and risks of MHT and recommend MHT without any underlying fear.
Keywords: Menopause; Perimenopause; Hormone Replacement Therapy; Tibolone; Hot Flashes
References
  1. Park CY, Lim JY, Park HY. Age at natural menopause in Koreans: secular trends and influences thereon. Menopause 2018; 25: 423-9.
    Pubmed CrossRef
  2. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001; 13: 453-64.
    Pubmed CrossRef
  3. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24: 728-53.
    Pubmed CrossRef
  4. Crandall CJ, Aragaki A, Cauley JA, Manson JE, LeBlanc E, Wallace R, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab 2015; 100: 524-34.
    Pubmed KoreaMed CrossRef
  5. Gast GC, Grobbee DE, Pop VJ, Keyzer JJ, Wijnands-van Gent CJ, Samsioe GN, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008; 51: 1492-8.
    Pubmed CrossRef
  6. Thurston RC, Aizenstein HJ, Derby CA, Sejdić E, Maki PM. Menopausal hot flashes and white matter hyperintensities. Menopause 2016; 23: 27-32.
    Pubmed KoreaMed CrossRef
  7. Worsley R, Bell R, Kulkarni J, Davis SR. The association between vasomotor symptoms and depression during perimenopause: a systematic review. Maturitas 2014; 77: 111-7.
    Pubmed CrossRef
  8. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med 2020; 382: 446-55.
    Pubmed CrossRef
  9. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21: 1063-8.
    Pubmed CrossRef
  10. Jehan S, Masters-Isarilov A, Salifu I, Zizi F, Jean-Louis G, Pandi-Perumal SR, et al. Sleep disorders in postmenopausal women. J Sleep Disord Ther 2015;4: 1000212.
    Pubmed KoreaMed CrossRef
  11. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
    Pubmed KoreaMed CrossRef
  12. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause:ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med 2017; 177: 1471-9.
    Pubmed KoreaMed CrossRef
  13. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009; 113: 65-73.
    Pubmed CrossRef
  14. Zeleke BM, Davis SR, Fradkin P, Bell RJ. Vasomotor symptoms and urogenital atrophy in older women: a systematic review. Climacteric 2015; 18: 112-20.
    Pubmed CrossRef
  15. Karim R, Dell RM, Greene DF, Mack WJ, Gallagher JC, Hodis HN. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011; 18: 1172-7.
    Pubmed KoreaMed CrossRef
  16. Islam S, Liu Q, Chines A, Helzner E. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005. Menopause 2009; 16: 77-83.
    Pubmed CrossRef
  17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
    Pubmed CrossRef
  18. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
    Pubmed CrossRef
  19. Thaung Zaw JJ, Howe PRC, Wong RHX. Postmenopausal health interventions:time to move on from the Women's Health Initiative? Ageing Res Rev 2018; 48: 79-86.
    Pubmed CrossRef
  20. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345: e6409.
    Pubmed CrossRef
  21. Gray G, Nelson-Piercy C. Thromboembolic disorders in obstetrics. Best Pract Res Clin Obstet Gynaecol 2012; 26: 53-64.
    Pubmed CrossRef
  22. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.
    Pubmed CrossRef
  23. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-14.
    Pubmed KoreaMed CrossRef
  24. Hodis HN, Sarrel PM. Menopausal hormone therapy and breast cancer:what is the evidence from randomized trials? Climacteric 2018; 21: 521-8.
    Pubmed KoreaMed CrossRef
  25. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019; 394: 1159-68.
    CrossRef
  26. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708.
    Pubmed KoreaMed CrossRef
  27. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-46.
    CrossRef
  28. Guthrie KA, LaCroix AZ, Ensrud KE, Joffe H, Newton KM, Reed SD, et al. Pooled analysis of six pharmacologic and nonpharmacologic interventions for vasomotor symptoms. Obstet Gynecol 2015; 126: 413-22.
    Pubmed KoreaMed CrossRef
  29. Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric 2019; 22: 544-52.
    Pubmed CrossRef
  30. Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med 2014; 174: 1058-66.
    Pubmed KoreaMed CrossRef
  31. Hill DA, Crider M, Hill SR. Hormone therapy and other treatments for symptoms of menopause. Am Fam Physician 2016; 94: 884-9.
    Pubmed
  32. Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 108: 41-8.
    Pubmed CrossRef
  33. Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med 2019; 24: 2515690X19829380.
    Pubmed KoreaMed CrossRef
  34. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, et al. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA 2016; 315: 2554-63.
    Pubmed CrossRef

This Article


Author ORCID Information

Services
Social Network Service

e-submission

Archives